Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
Abstract Background Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses. Molecular targeting therapy presents an opportunity to impede tumor through combination or sequential therapy, while th...
Main Authors: | Xia Liao, Ge Song, Zihan Xu, Yang Bu, Fan Chang, Fengan Jia, Xuelian Xiao, Xuejiao Ren, Mei Zhang, Qingan Jia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-019-6480-9 |
Similar Items
-
«Caractérisation de sept lignées cellulaires humaines de cancer de vessie pour les principaux marqueurs de la transition épithélio-mésenchymateuse, Twist1 et E-cadhérine, et pour une nouvelle drogue, le saracatinib. »
by: Lortal Canguilhem, Barbara
Published: (2012) -
Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma
by: Xia Liao, et al.
Published: (2019-12-01) -
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
by: Liwei Lang, et al.
Published: (2018-06-01) -
Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice
by: Xin-Ming Luo, et al.
Published: (2021-01-01) -
Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy
by: Hu X, et al.
Published: (2018-12-01)